Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer

Journal of Surgical Oncology

Volumn 106, Issue 1, 2012, Pages 24-30

  Hyslop, Terry ^a   Weinberg, David S ^b   Schulz, Stephanie ^a   Barkun, Alan ^c   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Colorectal cancer; Guanylyl cyclase C; Lymph node collection; Molecular staging; Occult tumor burden

Indexed keywords

GUANYLATE CYCLASE C; LYASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCCULT CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; ODDS RATIO; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TUMOR BURDEN;

EID: 84861996272     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23051     Document Type: Article

References (38)

1. Compton CC, Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004;54:295-308. (Pubitemid 40073988)
2. Edge SB, Byrd DR, Compton CC, et al.: AJCC cancer staging manual, New York: Springer; 2009.
3. Cunningham D, Atkin W, Lenz HJ, et al.: Colorectal cancer. Lancet 2010;375:1030-1047.
4. Siegel R, Ward E, Brawley O, et al.: Cancer statistics, 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;212:212-236.
5. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-487.
6. Quasar Collaborative G, Gray R, Barnwell J, et al.: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007;370:2020-2029.
7. Bilchik AJ, Hoon DS, Saha S, et al.: Prognostic impact of micrometastases in colon cancer: Interim results of a prospective multicenter trial. Ann Surg 2007;246:568-575; discussion 575-567.
8. Iddings D, Ahmad A, Elashoff D, et al.: The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: A meta-analysis. Ann Surg Oncol 2006;13:1386-1392. (Pubitemid 44749649)
9. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al.: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223-228.
10. Nicastri DG, Doucette JT, Godfrey TE, et al.: Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn 2007;9:563-571. (Pubitemid 350158413)
11. Waldman SA, Hyslop T, Schulz S, et al.: Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 2009;301:745-752.
12. Li P, Schulz S, Bombonati A, et al.: Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 2007;133:599-607. (Pubitemid 47187356)
13. Pitari GM, Li P, Lin JE, et al.: The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther 2007;82:441-447. (Pubitemid 47414353)
14. Birbe R, Palazzo JP, Walters R, et al.: Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol 2005;36:170-179. (Pubitemid 40313574)
15. Carrithers SL, Barber MT, Biswas S, et al.: Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA 1996;93:14827-14832. (Pubitemid 26419054)
16. Schulz S, Hyslop T, Haaf J, et al.: A validated quantitative assay to detect occult micrometastases by reverse transcriptasepolymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res 2006;12:4545-4552. (Pubitemid 44297803)
17. Cagir B, Gelmann A, Park J, et al.: Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med 1999;131:805-812.
18. Hyslop T, Weinberg DS, Schulz S, et al.: Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin Cancer Res 2011;17:3293-3303.
19. Beaulieu M, Desaulniers M, Bertrand N, et al.: Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon cancer. Diagn Mol Pathol 2010;19:20-27.
20. Haince JF, Houde M, Beaudry G, et al.: Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. J Clin Pathol 2010;63:530-537.
21. Sargent DJ, Resnick MB, Meyers MO, et al.: Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. Ann Surg Oncol 2011;18:3261-3270.
22. Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:2912-2919. (Pubitemid 46621841)
23. Swanson RS, Compton CC, Stewart AK, et al.: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003;10:65-71.
24. Hyslop T, Weinberg DS, Schulz S, et al.: Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer 2011.
25. Punt CJ, Buyse M, Kohne CH, et al.: Endpoints in adjuvant treatment trials: A systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007;99:998-1003. (Pubitemid 47232601)
26. Bozdogan H: Model selection and Akaike's information criterion (AIC): The general theory and its analytical extensions. Psychometrika 1987;52:345-370.
27. Biesheuvel CJ, Vergouwe Y, Steyerberg EW, et al.: Polytomous logistic regression analysis could be applied more often in diagnostic research. J Clin Epidemiol 2008;61:125-134.
28. Yee TW: The VGAM package for categorical data analysis. J Stat Software 2010;32:1-34.
29. Newcombe RG: Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med 1998;17:857-872.
30. Chien C, Morimoto LM, Tom J, et al.: Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer 2005;104:629-639. (Pubitemid 41022822)
31. Le H, Ziogas A, Lipkin SM, et al.: Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epidemiol Biomarkers Prev 2008;17:1950-1962.
32. White A, Vernon SW, Franzini L, et al.: Racial disparities in colorectal cancer survival: To what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics? Cancer 2010;116:4622-4631.
33. Hitchcock CL, Sampsel J, Young DC, et al.: Limitations with light microscopy in the detection of colorectal cancer cells. Dis Colon Rectum 1999;42:1046-1052. (Pubitemid 29383835)
34. Ratto C, Sofo L, Ippoliti M, et al.: Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum 1999;42:143-154; discussion 154-148.
35. Mejia A, Schulz S, Hyslop T, et al.: Molecular staging estimates occult tumor burden in colorectal cancer. Adv Clin Chem 2010;52:19-39.
36. O'Connell MJ, Lavery I, Yothers G, et al.: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:3937-3944.
37. Salazar R, Roepman P, Capella G, et al.: Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17-24.
38. Grothey A: Does stage II colorectal cancer need to be redefined? Clin Cancer Res 2011;17:3053-3055.